FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 331:785-791 September 22, 1994 Number 12 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Drug treatment of cardiac arrhythmias is not uniformly effective and frequently causes side effects. Recently, new data have become available that more clearly delineate the risks of antiarrhythmic-drug therapy. At the same time, establishing a benefit of treatment with these drugs has proved difficult. The potential benefits of antiarrhythmic therapy -- reductions in mortality or in symptoms related to arrhythmias -- as well as the potential risks are outlined in Table 1. In this review I shall consider the available data defining these risks and benefits (which have usually been delineated in specific groups of patients using specific drugs), . . . [Full Text of this Article]

Effects of Antiarrhythmic Therapy on Mortality

Effects of Antiarrhythmic Drugs on Arrhythmia-Related Symptoms

Provocation of Arrhythmias by Antiarrhythmic Drugs

Torsade de Pointes

Incessant Ventricular Tachycardia

Other Risks of Antiarrhythmic-Drug Therapy

An Approach to the Treatment of Arrhythmias

Whom to Treat for Specific Arrhythmias

Minimizing the Risks of Antiarrhythmic Therapy

Future Trends in Antiarrhythmic Therapy

Source Information

From the Division of Clinical Pharmacology, Vanderbilt University, 532C Medical Research Bldg., Nashville, TN 37232-6602, where reprint requests should be addressed to Dr. Roden.

References

This article has been cited by other articles:

• Hansen, M. L., Gadsboll, N., Gislason, G. H., Abildstrom, S. Z., Schramm, T. K., Folke, F., Friberg, J., Sorensen, R., Rasmussen, S., Poulsen, H. E., Kober, L., Madsen, M., Torp-Pedersen, C. (2008). Atrial fibrillation pharmacotherapy after hospital discharge between 1995 and 2004: a shift towards beta-blockers. Europace 10: 395-402 [Abstract] [Full Text]  
• Collins, H. L., DiCarlo, S. E. (2005). Acute exercise increases the ventricular arrhythmia threshold via the intrinsic adenosine receptor system in conscious hypertensive rats. Am. J. Physiol. Heart Circ. Physiol. 289: H1020-H1026 [Abstract] [Full Text]  
• Canyon, S. J., Dobson, G. P. (2004). Protection against ventricular arrhythmias and cardiac death using adenosine and lidocaine during regional ischemia in the in vivo rat. Am. J. Physiol. Heart Circ. Physiol. 287: H1286-H1295 [Abstract] [Full Text]  
• McNamara, R. L., Tamariz, L. J., Segal, J. B., Bass, E. B. (2003). Management of Atrial Fibrillation: Review of the Evidence for the Role of Pharmacologic Therapy, Electrical Cardioversion, and Echocardiography. ANN INTERN MED 139: 1018-1033 [Abstract] [Full Text]  
• Kasliwal, R. R, Mukesh, S., Manohar, G., Aggarwal, N., Bhatia, A. (2003). Pharmacotherapy of Atrial Fibrillation. Asian Cardiovasc. Thorac. Ann. 11: 364-374 [Abstract] [Full Text]  
• Rolf, S., Bruns, H.-J., Wichter, T., Kirchhof, P., Ribbing, M., Wasmer, K., Paul, M., Breithardt, G., Haverkamp, W., Eckardt, L. (2003). The ajmaline challenge in Brugada syndrome: Diagnostic impact, safety, and recommended protocol. Eur Heart J 24: 1104-1112 [Abstract] [Full Text]  
• Al-Khatib, S. M., LaPointe, N. M. A., Kramer, J. M., Califf, R. M. (2003). What Clinicians Should Know About the QT Interval. JAMA 289: 2120-2127 [Abstract] [Full Text]  
• Wellens, H. J.J. (2002). Contemporary Management of Atrial Flutter. Circulation 106: 649-652 [Full Text]  
• Plewan, A. (2002). A reply. Eur Heart J 23: 586-586 [Full Text]  
• Darpo, B. (2001). Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes. Eur Heart J Suppl 3: K70-K80 [Abstract]  
• Plewan, A, Lehmann, G, Ndrepepa, G, Schreieck, J, Alt, E.U, Schomig, A, Schmitt, C (2001). Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation. Sotalol vs bisoprolol. Eur Heart J 22: 1504-1510 [Abstract]  
• Zebe, H. (2000). Atrial fibrillation in dialysis patients. Nephrol Dial Transplant 15: 765-768 [Full Text]  
• Kreiss, Y., Sidi, Y., Gur, H. (1999). Efficacy and safety of intravenous amiodarone in recent-onset atrial fibrillation: experience in patients admitted to a general internal medicine department. Postgrad. Med. J. 75: 278-281 [Abstract] [Full Text]  
• Yong, S. L., Xu, R., McLarnon, J. G., Zolotoy, A. B., Beatch, G. N., Walker, M. J. A. (1999). RSD1000: A Novel Antiarrhythmic Agent with Increased Potency under Acidic and High-Potassium Conditions. J. Pharmacol. Exp. Ther. 289: 236-244 [Abstract] [Full Text]  
• Chung, M. K., Schweikert, R. A., Wilkoff, B. L., Niebauer, M. J., Pinski, S. L., Trohman, R. G., Kidwell, G. A., Jaeger, F. J., Morant, V. A., Miller, D. P., Tchou, P. J. (1998). Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required?: yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications. J Am Coll Cardiol 32: 169-176 [Abstract] [Full Text]  
• Grace, A. A., Camm, A. J. (1998). Quinidine. NEJM 338: 35-45 [Full Text]  
• Sweeney, M. O., Ruskin, J. N., Garan, H., McGovern, B. A., Guy, M. L., Torchiana, D. F., Vlahakes, G. J., Newell, J. B., Semigran, M. J., Dec, G. W. (1995). Influence of the Implantable Cardioverter/Defibrillator on Sudden Death and Total Mortality in Patients Evaluated for Cardiac Transplantation. Circulation 92: 3273-3281 [Abstract] [Full Text]  
• Pinski, S. L., Fahy, G. J. (1995). The Proarrhythmic Potential of Implantable Cardioverter-Defibrillators. Circulation 92: 1651-1664 [Abstract] [Full Text]  
• Gillis, A. M., Sheldon, R. S., Wyse, D. G., Leitch, J. W., Yee, R., Klein, G. J., Duff, H. J., Mitchell, L. B. (1995). Long-term Reproducibility of Ventricular Tachycardia Induction in Patients With Implantable Cardioverter/Defibrillators : Serial Noninvasive Studies. Circulation 91: 2605-2613 [Abstract] [Full Text]